|Table of Contents|

Expression level of serum HSP90 mRNA and β2-MG in patients with multiple myeloma and its relationship with prognosis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 10
Page:
1875-1879
Research Field:
Publishing date:

Info

Title:
Expression level of serum HSP90 mRNA and β2-MG in patients with multiple myeloma and its relationship with prognosis
Author(s):
LI Yongli1; FU Qiongyao1; ZHAO Lian2; WANG Danmei3
1.School of Tropical Medicine,Hainan Medical University,Hainan Haikou 571199,China;2.The First Affiliated Hospital of Hainan Medical University,Hainan Haikou 570102,China;3.School of Basic Medicine and Life Sciences,Hainan Medical University,Hainan Haikou 571199,China.
Keywords:
multiple myeloma; heat shock protein 90; β2-microglobulin; prognosis
PACS:
R739.42
DOI:
10.3969/j.issn.1672-4992.2023.10.019
Abstract:
Objective:To investigate the relationship between the expression levels of heat shock protein 90 (HSP90) mRNA and β2-microglobulin (β2-MG) and prognosis in patients with multiple myeloma.Methods:A total of 94 patients with multiple myeloma admitted to our hospital were selected as myeloma group,and divided into ISS stage I (26 cases),ISS II stage (36 cases) and ISS III stage (32 cases).At the same time,96 healthy people were selected as the healthy control group.Real-time quantitative PCR (qRT-PCR) was used to detect the expression level of HSP90 mRNA in serum.Enzyme linked immunosorbent assay (ELISA) was used to detect the expression level of serum β2-MG.Pearson method was used to analyze the correlation between serum HSP90 mRNA level and β2-MG level in patients with multiple myeloma.Kaplan-Meier method was used to analyze the relationship between the prognosis of patients with multiple myeloma and the expression levels of serum HSP90 mRNA and β2-MG.The prognostic factors of multiple myeloma patients was analyzed by Cox regression analysis.Results:The levels of serum HSP90 mRNA and β2-MG in myeloma group were significantly higher than those in healthy control group (P＜0.001).The levels of serum HSP90 mRNA and β2-MG in patients with multiple myeloma in ISS stage III were higher than those in patients in ISS stage II and ISS stage I.The levels of serum HSP90 mRNA and β2-MG in patients with ISS stage II were higher than those in patients with ISS stage I (P＜0.001).There was a positive correlation between serum HSP90 mRNA level and β2-MG level in patients with multiple myeloma (r=0.630,P＜0.001).The 3-year survival rate (35.42%) of multiple myeloma patients with high expression of HSP90 mRNA was lower than that (63.04%) of patients with low expression of HSP90 mRNA (P＜0.01).The 3-year survival rate (35.56%) of multiple myeloma patients with high expression of β2-MG was lower than that (61.22%) of patients with low expression of β2-MG (P＜0.05).Serum HSP90 mRNA and β2-MG were independent risk factors of prognosis in patients with multiple myeloma (P＜0.05).Conclusion:HSP90 mRNA and β2-MG are highly expressed in the serum of patients with multiple myeloma.The detection of the levels of HSP90 mRNA and β2-MG has potential reference value for evaluating the condition and prognosis of patients with multiple myeloma.

References:

[1]ORLOWSKI RZ,MOREAU P,NIESVIZKY R,et al.Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma:updated overall survival,safety,and subgroups［J］.Clin Lymphoma Myeloma Leuk,2019,19(8):522-530.
[2]程灵灵,魏晓晶,庄婧,等.miR-21与多发性骨髓瘤患者预后的关系及其对化疗耐药的影响和机制［J］.山东医药,2020,60(2):14-17. CHENG LL,WEI XJ,ZHUANG J,et al.Relationship between miR-21 and prognosis of patients with multiple myeloma and its effect and mechanism on chemotherapy resistance［J］.Shandong Medical Journal,2020,60(2):14-17.
[3]SHARP SY,BOXALL K,ROWLANDS M,et al.Correction:in vitro biological characterization of a novel,synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors［J］.Cancer Res,2019,79(1):287.
[4]张煜,陈宏梅,卢旭,等.多发性骨髓瘤患者血清外泌体miR-223-3p的表达及临床意义［J］.中华检验医学杂志,2020,43(4):446-451. ZHANG Y,CHEN HM,LU X,et al.Expression and clinical value of serum exosomal miR-223-3p in multiple myeloma patients［J］.Chinese Journal of Laboratory Medicine,2020,43(4):446-451.
[5]GREIPP PR,SAN-MIQUEL J,DURIE BG,et al.International staging system for multiple myeloma［J］.J Clin Oncol,2005,23(15):3412-3420.
[6]中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2020年修订)［J］.中华内科杂志,2020,59(5):341-346. Chinese Hematology Association,Chinese Society of Hematology,Chinese Myeloma Committee-Chinese Hematology Association.The guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)［J］.Chinese Journal of Internal Medicine,2020,59(5):341-346.
[7]SAKA B,SAYITOGLU M,ISTEMIHAN Z,et al.The role of local bone marrow renin-angiotensin system in multiple myeloma［J］.Turk J Haematol,2019,36(3):178-185.
[8]RICHARDSON PG,HOFMEISTER CC,ROSENBAUM CA,et al.Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma［J］.Br J Haematol,2018,182(2):231-244.
[9]ZHANG WL,CAO L,LIU XN,et al.High expression of CHML predicts poor prognosis of multiple myeloma［J］.J Cancer,2019,10(24):6048-6056.
[10]DONG W,YU P,ZHANG T,et al.Adrenomedullin serves a role in the humoral pathway of delayed remote ischemic preconditioning via a hypoxia-inducible factor-1α-associated mechanism［J］.Mol Med Rep,2018,17(3):4547-4553.
[11]姚梦俐,陈婷梅,李朴.脑脊液β2-微球蛋白用于急性淋巴细胞白血病中枢浸润患者的预后评估［J］.中国实验血液学杂志,2022,30(1):113-118. YAO ML,CHEN TM,LI P.Cerebrospinal fluid β2-microglobulin for prognostic evaluation of patients with central nervous system infiltration in acute lymphoblastic leukemia［J］.Journal of Experimental Hematology,2022,30(1):113-118.
[12]徐玉秀,姜芳,马东升,等.多发性骨髓瘤患者的循环骨髓瘤细胞与髓内瘤细胞负荷状况研究［J］.实用癌症杂志,2020,35(4):549-551. XU YX,JIANG F,MA DS,et al.The study of circulating myeloma cells and intramedullary tumor cell load condition in patients with multiple myeloma［J］.The Practical Journal of Cancer,2020,35(4):549-551.
[13]TABATA M,TSUBAKI M,TAKEDA T,et al.Inhibition of HSP90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells［J］.Clin Exp Med,2020,20(1):63-71.
[14]刘湲,刘伟,张素芳,等.多发性骨髓瘤骨髓组织中miR-181a表达量与肿瘤细胞增殖、迁移的相关性［J］.海南医学院学报,2018,24(17):1607-1610. LIU Y,LIU W,ZHANG SF,et al.Correlation of miR-181a expression in bone marrow tissues of multiple myeloma with tumor cell proliferation and migration［J］.Journal of Hainan Medical University,2018,24(17):1607-1610.
[15]GAO C,PENG YN,WANG HZ,et al.Inhibition of heat shock protein 90 as a novel platform for the treatment of cancer［J］.Curr Pharm Des,2019,25(8):849-855.
[16]谭鑫.多发性骨髓瘤患者血清β2-微球蛋白,TNF-α,CRP及IL-6水平检测［J］.中国现代医生,2019,57(26):13-16. TAN X.Values of detecting the levels of β2-MG,TNF-α,CRP,IL-6 in the patients with multiple myeloma［J］.Modern Chinese Doctor,2019,57(26):13-16.
[17]孙延庆,李青芬,张启科,等.中性粒细胞/淋巴细胞比值在多发性骨髓瘤患者预后中的意义［J］.中国实验血液学杂志,2019,27(2):489-493. SUN YQ,LI QF,ZHANG QK,et al.Significance of neutrophil/lymphocyte ratio in the prognosis of patients with multiple myeloma［J］.Journal of Experimental Hematology,2019,27(2):489-493.

Memo

Memo:
National Natural Science Foundation of China(No.81360306）；国家自然科学基金项目（编号：81360306）
Last Update: 1900-01-01